Form 8-K - Current report:
SEC Accession No. 0001558370-25-000008
Filing Date
2025-01-02
Accepted
2025-01-02 08:45:12
Documents
13
Period of Report
2025-01-01
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K lvtx-20250101x8k.htm   iXBRL 8-K 43931
  Complete submission text file 0001558370-25-000008.txt   168499

Data Files

Seq Description Document Type Size
2 EX-101.SCH lvtx-20250101.xsd EX-101.SCH 3308
3 EX-101.LAB lvtx-20250101_lab.xml EX-101.LAB 16529
4 EX-101.PRE lvtx-20250101_pre.xml EX-101.PRE 10843
16 EXTRACTED XBRL INSTANCE DOCUMENT lvtx-20250101x8k_htm.xml XML 4972
Mailing Address YALELAAN 62 UTRECHT P7 3584 CM
Business Address YALELAAN 62 UTRECHT P7 3584 CM 31 6 3000 3035
LAVA Therapeutics NV (Filer) CIK: 0001840748 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40241 | Film No.: 25500385
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)